 Lille, France; Cambridge, MA; January 27, 2021 - GENFIT Nasdaq and Euronext: GNFT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases the Company, today announced that technical corrections were made to the voting results of the holders of the convertible bonds issued by the Company on October 16, 2017 the OCEANEs at the Bondholders Meeting which took place on January 25, 2021 the Bondholders Meeting. These corrections have no impact on the fact that all of the resolutions by the Bondholders Meeting were approved, and are the result of corrections made by BNP Paribas Securities Services, the external provider in charge of centralizing the Bondholders Meeting votes. They are not the result of any action or responsibility of the Company. 